Buy Tirzepatide — Dual GLP-1/GIP for Weight Loss
Tirzepatide is a 39-amino-acid synthetic dual agonist of the GLP-1 and GIP receptors, developed by Eli Lilly and approved by the FDA in 2022 under the brand name Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It was the first incretin-class drug to combine GLP-1 and GIP activation in a single molecule, and the SURPASS and SURMOUNT clinical trial programmes have produced the most extensive efficacy data set of any peptide in the obesity and diabetes research space.Mechanism of actionBy co-activating GLP-1 and GIP receptors, tirzepatide augments glucose-dependent insulin secretion, suppresses glucagon in hyperglycaemic states, slows gastric emptying, and reduces appetite via central pathways. The addition of GIP agonism to GLP-1 agonism appears to enhance weight-loss efficacy by further modulating adipose tissue lipid handling and counteracting GLP-1-induced nausea — two mechanistic advantages that distinguish tirzepatide from earlier single-agonist molecules.Evidence from peer-reviewed researchThe pivotal SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, reported mean weight reductions of 20.9% (10 mg) and 22.5% (15 mg) at 72 weeks in adults with obesity without diabetes. The SURPASS-2 head-to-head trial (NEJM 2021) compared tirzepatide with semaglutide 1 mg in type 2 diabetes and demonstrated superior glycaemic and weight outcomes across all three tirzepatide doses. SURPASS-1 (Lancet 2021) established monotherapy efficacy and safety.Typical research protocolsIn research use, tirzepatide is administered subcutaneously once weekly at doses escalated from 2.5 mg to 15 mg over the first 20 weeks to reduce gastrointestinal side-effects. The weekly dosing schedule and gradual titration are hallmarks of the SURPASS and SURMOUNT trial designs.Quality and purityPEPTEX tirzepatide is synthesised to ≥99% purity under ISO conditions, lyophilised from buffer, and certified by HPLC. Research use only — not for human consumption.Storage and handlingStore lyophilised tirzepatide at −20 °C, protected from light, for up to 24 months. After reconstitution with bacteriostatic water, store at 2–8 °C and use within 12 weeks.
Price: EUR | Brand: PEPTEX | In Stock | EU-wide delivery, 3-5 business days
Rating: 5/5 (546 reviews)
Customer Reviews
Marta — ★★★★
Effective but shipping to Netherlands took 8 days last time. First order arrived in 4. Product itself is consistent though.
Marta P. — ★★★★★
packaging impressed me honestly. double insulated, cold packs still frozen after 4 days in transit to Madrid. the powder dissolved perfectly. on week 6 now and eating about 40% less without trying
Daisy — ★★★★★
This is my go-to for weight management research now. Five orders in, never disappointed. Support team actually knows what they're talking about which is rare in this space.
Nicolas D. — ★★★
Works but the GI side effects at 7.5mg were rough for me. Stayed at 5mg which is more tolerable. Results are slower but consistent. Product quality itself is fine, just wish my stomach agreed with higher doses.
Günther — ★★★★★
My husband and I both use tirzepatide from peptex. He's on 10mg, I'm on 5mg. Both seeing steady progress. The fact that you can adjust the dose with vials gives us flexibility that pens don't offer. Third order for both of us.
Available Sizes
- 10mg — 69 EUR
- 30mg — 169 EUR
- 60mg — 309 EUR
Storage Recommendations
| Condition | Temperature | Duration |
|---|---|---|
| Lyophilised | -20°C | Up to 24 months |
| Reconstituted | 2-8°C | Up to 12 weeks with bacteriostatic water |
Research References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — NEJM / PubMed (2022)
- Tirzepatide versus Semaglutide in Type 2 Diabetes — NEJM / PubMed (2021)
- Efficacy of tirzepatide in type 2 diabetes (SURPASS-1 trial) — Lancet / PubMed (2021)
Frequently Asked Questions
What is Tirzepatide and how does it help with weight loss?
Tirzepatide is a dual-action peptide that targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors simultaneously. Thanks to its dual mechanism of action, Tirzepatide effectively reduces appetite, decreases portion sizes, and slows gastric emptying, leading to sustained weight loss. In clinical studies, participants lost an average of 15–22% of their initial body weight while following a proper diet. Tirzepatide is administered just once a week, making it a convenient solution for long-term weight management.
How to properly use Tirzepatide and what dosage is recommended?
Tirzepatide is administered subcutaneously once per week. Gradual dose escalation is recommended once per month following this schedule: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg. After reaching the maximum dose of 15 mg per week, the peptide is used until the target weight is achieved. The course can continue for several years. For best results, Tirzepatide is recommended to be combined with Cagrilintide. The peptide is reconstituted in bacteriostatic water for long-term storage up to 90 days.
What results can I expect from Tirzepatide and how soon will they appear?
The first noticeable results from Tirzepatide typically appear within the first 4–8 weeks — appetite reduction and decreased food cravings begin within the first days of use. Over a 3–6 month course with proper nutrition, weight loss of 10–15% can be expected. With longer use and reaching maximum dosage, results can reach up to 20–22% of initial body weight. Beyond weight loss, users report improved metabolic parameters, normalized blood sugar levels, and increased overall energy levels.
How is Tirzepatide different from other weight loss peptides?
Tirzepatide features a unique dual mechanism of action — it simultaneously targets both GIP and GLP-1 receptors, while most analogues act on only one receptor type. This provides a more pronounced appetite suppression effect and more significant weight loss compared to single-action peptides. Clinical studies show Tirzepatide achieves average weight loss of 15–22%, which is among the best results for peptide-based treatments. When combined with Cagrilintide, effectiveness increases even further.
What side effects can occur when taking Tirzepatide?
As with most peptides affecting the gastrointestinal tract, temporary side effects may occur at the beginning of the course or when increasing dosage: mild nausea, stomach discomfort, and reduced appetite. These effects are typically adaptive in nature and resolve within 1–2 weeks. Gradual dose escalation (once per month) significantly reduces the likelihood and intensity of side effects. Unlike stimulant-containing products, Tirzepatide does not affect the nervous system and does not cause increased blood pressure or heart rate.
Where to buy Tirzepatide with delivery to Europe?
You can buy Tirzepatide with delivery throughout Europe at the Peptex online store. We offer original high-quality peptide with purity certificates, fast delivery to EU countries, secure packaging with temperature control, and professional support for dosage selection. Orders can be placed at peptex.shop with payment by card or cryptocurrency. All orders include detailed usage instructions.
How to store Tirzepatide and what is its shelf life?
In lyophilized (dry) form, Tirzepatide is stored in a refrigerator at 2–8°C. In this form, the peptide retains activity for up to 24 months. After reconstitution in bacteriostatic water, the solution is stored in the refrigerator for up to 90 days. Important: do not freeze the prepared solution, avoid exposure to direct sunlight, and use sterile syringes each time you draw solution from the vial.
💬 Комментарии